The Manufacturers Life Insurance Company Grows Stake in Gossamer Bio, Inc. (NASDAQ:GOSS)

The Manufacturers Life Insurance Company boosted its position in Gossamer Bio, Inc. (NASDAQ:GOSS) by 24.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 385,133 shares of the company’s stock after purchasing an additional 74,920 shares during the period. The Manufacturers Life Insurance Company’s holdings in Gossamer Bio were worth $380,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of GOSS. NEA Management Company LLC increased its stake in Gossamer Bio by 14.2% in the 2nd quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock valued at $16,300,000 after purchasing an additional 2,255,025 shares in the last quarter. Monaco Asset Management SAM boosted its holdings in shares of Gossamer Bio by 390.3% during the second quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company’s stock worth $2,456,000 after purchasing an additional 2,170,104 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Gossamer Bio by 170.8% during the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock worth $3,002,000 after purchasing an additional 2,103,766 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Gossamer Bio by 204.7% during the second quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company’s stock worth $1,844,000 after purchasing an additional 1,375,000 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in shares of Gossamer Bio by 31.3% during the second quarter. Acadian Asset Management LLC now owns 3,592,765 shares of the company’s stock worth $3,235,000 after purchasing an additional 856,380 shares during the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Stock Up 2.2 %

NASDAQ:GOSS opened at $0.93 on Monday. The firm has a market capitalization of $210.74 million, a PE ratio of -2.91 and a beta of 1.85. The stock has a 50 day moving average of $0.84 and a 200-day moving average of $0.87. Gossamer Bio, Inc. has a 52 week low of $0.50 and a 52 week high of $1.60. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $9.48 million during the quarter, compared to the consensus estimate of $4.52 million. Analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Gossamer Bio in a research report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Gossamer Bio presently has an average rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.